CN104161261A - Composition for strengthening immunity function of organism and preparation method thereof - Google Patents
Composition for strengthening immunity function of organism and preparation method thereof Download PDFInfo
- Publication number
- CN104161261A CN104161261A CN201410354033.6A CN201410354033A CN104161261A CN 104161261 A CN104161261 A CN 104161261A CN 201410354033 A CN201410354033 A CN 201410354033A CN 104161261 A CN104161261 A CN 104161261A
- Authority
- CN
- China
- Prior art keywords
- composition
- preparation
- parts
- spore powder
- lucidum spore
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 93
- 230000036039 immunity Effects 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 238000005728 strengthening Methods 0.000 title claims abstract description 6
- 239000000843 powder Substances 0.000 claims abstract description 40
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 20
- 239000000284 extract Substances 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 229940068517 fruit extracts Drugs 0.000 claims abstract description 3
- 229940107666 astragalus root Drugs 0.000 claims description 37
- 244000163122 Curcuma domestica Species 0.000 claims description 17
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 17
- 235000003373 curcuma longa Nutrition 0.000 claims description 17
- 235000013399 edible fruits Nutrition 0.000 claims description 17
- 235000013976 turmeric Nutrition 0.000 claims description 17
- 239000002775 capsule Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- 230000002708 enhancing effect Effects 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- 235000013376 functional food Nutrition 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 22
- 241000222336 Ganoderma Species 0.000 abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 6
- 235000006533 astragalus Nutrition 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 3
- 241000045403 Astragalus propinquus Species 0.000 abstract 2
- 238000003908 quality control method Methods 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 235000020240 turmeric extract Nutrition 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 49
- 241000699666 Mus <mouse, genus> Species 0.000 description 33
- 239000003795 chemical substances by application Substances 0.000 description 16
- 230000037396 body weight Effects 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 8
- 230000036737 immune function Effects 0.000 description 8
- 230000000242 pagocytic effect Effects 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 238000007689 inspection Methods 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 4
- 235000012754 curcumin Nutrition 0.000 description 4
- 229940109262 curcumin Drugs 0.000 description 4
- 239000004148 curcumin Substances 0.000 description 4
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 238000005498 polishing Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000005180 public health Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241001061264 Astragalus Species 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 2
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011122 softwood Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 238000009602 toxicology test Methods 0.000 description 2
- 235000020985 whole grains Nutrition 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 201000001376 Familial Combined Hyperlipidemia Diseases 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000011207 functional examination Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000007674 genetic toxicity Effects 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 239000008235 industrial water Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a composition for strengthening the immunity function of an organism and a preparation method thereof. The composition is mainly prepared from the following raw materials in parts by weight: 67-201 parts of glossy ganoderma spore powder, 33.5-100.5 parts of astragalus membranaceus extracts, 25-75 parts of glossy privet fruit extracts, and 17.5-52.5 parts of turmeric extracts. A modern preparation technology is used, and an advanced quality control method is used, so that products are safe, stable and controllable. Animal experiments prove that compared with a preparation made of single glossy ganoderma spore powder and a preparation made of single astragalus membranaceus extracts, the composition disclosed by the invention has more excellent effects of strengthening the immunity of the organisms under the condition of the same dosage, and in addition, the composition does not have any toxic or side effects, so that the composition has higher development and utilization values and market application prospects.
Description
Technical field
The present invention relates to a kind of functional food, be specially a kind of composition and method of making the same that strengthens immunity function that has.
Background technology
Immunity is the defense mechanism of human body self, is identification and eliminates external intrusion foreign matter, processes the ability of self cell and identification and processing vivo mutations cell and the virus infected cell of old and feeble, damage, dead, sex change.The too low body that makes of immunologic function can not be removed harmful material in time, for the foreign substance irresistance of invasion, tumour and various cause pathogeny imcrobe infection easily occurs.
Modern society's ubiquity physique declines, the phenomenon that chronic disease is multiple.Main cause is long-term work, overwork, caused that vigor goes down, respond goes down and adaptive capacity goes down, thereby physique declines, immunity of organism resistance reduces.A global investigation of WHO shows that 75% people is in sub-health state.Immunity degradation becomes a large secret worry of modern's health gradually.
Present composition screening has the Chinese medical extract and the lucidum spore powder composition that strengthen immunity of organisms, scientific formulation is reasonable, can strengthen body hypoxia-bearing, cold-resistant, antineoplastic ability, regulate the non-specific and specific immune function of human body, there is effect comprehensive and system enhancing immunity of organisms, especially can strengthen immunologic hypofunction crowd's immunity, strengthen the ability of body opposing pathogenic infection, improve body health level.
Summary of the invention
The object of the present invention is to provide a kind of composition that strengthens body immunity function that has.
Another object of the present invention is to provide the preparation method of described composition.
The present invention also aims to provide the purposes of described composition.
The present invention also aims to provide the functional food that contains described composition.
In order to realize object of the present invention, the present invention is for strengthening the composition of immunity of organisms, and it mainly adopts the raw material of following weight portion to make:
Lucidum spore powder 67-201 part, Astragalus Root P.E 33.5-100.5 part, glossy privet fruit extract 25-75 part, Turmeric P.E 17.5-52.5 part.
Wherein, preferably adopt the raw material of following weight portion to make:
134 parts of lucidum spore powders, 67 parts of Astragalus Root P.Es, 50 parts of glossy privet fruit extracts, 35 parts of Turmeric P.Es.
Composition of the present invention, it also contains one or more auxiliary materials in microcrystalline cellulose, dolomol, dextrin or sucrose, or the conventional preparation auxiliary material in other this areas.
Composition of the present invention, prepares by the following method: get respectively supplementary material according to above-mentioned weight portion, cross after 80 mesh sieves, through batching, the steps such as mixing are made preparation.
Primary raw material effect of the present invention is as follows:
1, lucidum spore powder: glossy ganoderma effect is invigorating qi for tranquilization, relieving cough and asthma.Reishi sporule is the glossy ganoderma growth and maturity phase to eject ultrafine spore from cap, for the reproduction cell of glossy ganoderma, there is the whole hereditary active material of glossy ganoderma, main active ingredient is except polysaccharide, triterpenes, peptide class, also be rich in several amino acids, oligosaccharides, aliphatic acid and trace element, there is pharmacological action widely, wherein more antitumor and immunoregulation effect.Pharmacological testing research shows, lucidum spore powder can strengthen mouse cell immunity and humoral immunity, has immunologic enhancement.Lucidum spore powder can significantly strengthen the immunologic function of glucocorticoid immunosuppressed mice, thymus index and spleen index, the hemolysin that can significantly improve mouse are tired, increase peritoneal macrophage and Phagocytic Function, in human peripheral blood, the content of the quantity of T, B, NK cell, total complement of serum activity and major cytokine all has certain influence.
2, Astragalus Root P.E: Radix Astragali effect is tonifying Qi and lifting yang, strengthening exterior and reducing sweat, inducing diuresis for removing edema, promotes the production of body fluid and nourishes blood, the stagnant logical numbness of row, pus draining and toxin expelling, expelling pus and promoting granulation.Astragalus Root P.E active ingredient is mainly Astragaloside IV and astragalus polyose.Pharmacological testing research shows, Astragalus Root P.E can obviously raise because of endoxan (CTX) reduces normally or lotus knurl (S180) mouse thymus index, its effect is relevant with drug dose.Astragalus Root P.E can make
phagocytic rate and the phagocytic index of engulfing chicken red blood cell significantly raise.The gross mass that can significantly increase Mouse Weight and immune organ taking active component astragalus polyose as main Astragalus Root P.E, can obviously improve body's immunity and antioxidative functional, and mouse lymphocyte propagation is had to very strong facilitation.Astragalus Root P.E can promote the propagation of PMBC, improve the killing activity of T cell to tumour cell, strengthen peripheral blood and adhere to the function of engulfing and produce cell factor of monocyte to tumour cell, promote peripheral blood B cell to produce IgG, human immunity function is had to humidification.
3, glossy privet fruit extract: fruit of glossy privet effect is nourishing liver and kidney, crow sends out in improving eyesight.Main active has oleanolic acid, fruit of glossy privet acid, ursolic acid.Pharmacological testing research shows, the fruit of glossy privet not only has the function that strengthens cellular immunity and humoral immunity, can also and improve the number of ways such as its gene expression and bring into play its immune enhancing function by Cytokines Production.Glossy privet fruit extract can obviously increase immunosuppressed mice immune organ weight, and can suppress the reduction of its body weight, has increase Function of lymphocyte transform and the macrophage phagocytic function of dose dependent.
4, Turmeric P.E: turmeric effect is for broken blood gas, inducing meastruation to relieve menalgia.Its active ingredient is volatile oil and curcumin.Pharmacological testing research shows, the ethyl acetate extract of turmeric rhizome has the allergic activity of inhibition test animal I type familial combined hyperlipidemia, suppresses mast cell histamine release.Curcumin can make kinds of tumor cells be gathered in the S phase, can not enter next cell generation cycle and it is had to obvious inhibitory action, and lethal effect is more responsive to proliferation period cell, inducing apoptosis of tumour cell.Curcumin can obviously improve the killer cell activity of NK, Lymphokine, increases CD in spleen
4+, CD
8+the number of cell, thus cellular immune function regulated.Curcumin has the effect that regulates body's immunity, and relevant to dosage, and possible mechanism is relevant with the activity that suppresses NF-к B.
The formulation of the present composition is that medically acceptable various peroral dosage forms comprise capsule, tablet, granule or oral liquid, is preferably capsule or tablet.
The present invention also provides the preparation method of above-mentioned composition, and the above-mentioned method of making various oral formulations adopts this area common method, and for example the preparation method of present composition capsule, comprises the steps:
(1) supplementary material is crossed respectively 80 mesh sieves, for subsequent use.
(2) accurately take lucidum spore powder, Astragalus Root P.E, glossy privet fruit extract, Turmeric P.E, microcrystalline cellulose by formula inventory; put in mixer and mix 30 minutes; then add appropriate amount of ethanol to make the softwood of " that holds is agglomerating; that touches is loose "; granulate with oscillating granulator rapidly; cross 18 mesh sieves, obtain wet granular.
(3) wet granular is laid in stainless steel disc uniformly, puts in air dry oven and be dried, forced air drying a period of time under preference temperature, then dried particle is crossed to the whole grain of 18 mesh sieves, for subsequent use.
(4) separately accurately take dolomol by formula inventory, first increase progressively and mix after three times with dried particle equivalent, add total mixing 30 minutes in total mixing device, obtain always mixed particle.After getting total mixed particle, dress grain is made capsule.
(5) use polishing machine to carry out polishing to capsule.
(6) packaging, inspection obtain standard compliant finished product.
The present invention also provides the application of described composition in the functional food for the preparation of enhancing immunity of organisms.
The present invention also provides described composition to improve the application in the functional food of sub-health state in preparation.
In addition, the present invention also provides the functional food that contains above-mentioned composition.
Advantage of the present invention and feature: screening has the Radix Astragali that strengthens immunity of organisms, the fruit of glossy privet, the Chinese medical extract of turmeric and lucidum spore powder composition, scientific formulation is reasonable, can play resistance to anoxic to body, cold-resistant, antineoplastic immune effect, there is the effect of more excellent enhancing immunity of organisms than single lucidum spore powder preparation under same dose and single Astragalus Root P.E preparation, and without any side effects, it is a kind of composition of good enhancing immunity of organisms, it has proportioning equilibrium, easily absorb, the feature such as with strong points, simultaneously, adopt scientific and reasonable technique to be prepared from, quality controllable, take safety, can effectively strengthen immunity of organisms, be suitable for numerous crowds edible for a long time.
Detailed description of the invention:
Below in conjunction with detailed description of the invention, the present invention is described in further detail, but content of the present invention is not limited to lifted embodiment.In following examples, lucidum spore powder, purchased from Hangzhou Zhong Zhikang mushroom Bioisystech Co., Ltd; Astragalus Root P.E (Astragaloside IV >=0.5%), glossy privet fruit extract (10:1), Turmeric P.E (10:1) is all purchased from Yuan Sen bio tech ltd, Xi'an.
Embodiment 1:
The formula of product of the present invention: lucidum spore powder 134g, Astragalus Root P.E 67g, glossy privet fruit extract 50g, Turmeric P.E 35g, microcrystalline cellulose 32.4g, dolomol 1.6g.
Preparation method:
1, supplementary material is crossed respectively 80 mesh sieves, for subsequent use.Industrial water is purified water, should meet " Chinese pharmacopoeia " 2010 editions purified water requirements; Producing ethanol used is food grade ethanol, should meet the requirement of GB-10343-2008 edible alcohol.
2, accurately take lucidum spore powder, Astragalus Root P.E, glossy privet fruit extract, Turmeric P.E, microcrystalline cellulose by formula inventory; put in mixer and mix 30 minutes; then add appropriate amount of ethanol to make the softwood of " that holds is agglomerating; that touches is loose "; granulate with oscillating granulator rapidly; cross 18 mesh sieves, obtain wet granular.
3, wet granular is laid in stainless steel disc uniformly, puts in air dry oven and be dried, forced air drying a period of time under preference temperature, then dried particle is crossed to the whole grain of 18 mesh sieves, for subsequent use.
4, separately accurately take dolomol by formula inventory, first increase progressively and mix after three times with dried particle equivalent, add total mixing 30 minutes in total mixing device, obtain always mixed particle.After getting total mixed particle, dress grain is made capsule.
5, use polishing machine to carry out polishing to capsule.
6, packaging, inspection obtain standard compliant finished product.
Embodiment 2:
The formula of product of the present invention: lucidum spore powder 201g, Astragalus Root P.E 33.5g, glossy privet fruit extract 25g, Turmeric P.E 26.5g, microcrystalline cellulose 211g, dolomol 3g.
Preparation method: supplementary material mixes, sieves, and compressing tablet is made tablet, and package test obtains standard compliant product.
Embodiment 3:
The formula of product of the present invention: lucidum spore powder 67g, Astragalus Root P.E 100.5g, glossy privet fruit extract 66g, Turmeric P.E 52.5g, dextrin 214g.
Preparation method: supplementary material mixes, sieves, granulates, and granulation agent, package test obtains standard compliant product.
Embodiment 4:
The formula of product of the present invention: lucidum spore powder 150g, Astragalus Root P.E 43.5g, glossy privet fruit extract 75g, Turmeric P.E 17.5g, sucrose 45g.
Preparation method: supplementary material mixes, the appropriate dissolving that add water, filters, and makes oral liquid.Package test obtains standard compliant product.
Further set forth the present invention by toxicological test and animal function test below, due to capsule involved in the present invention, tablet, granule, oral liquid, except formulation, auxiliary material difference, primary raw material, every day, amount, effective component were all identical, do not affect safety and the function of product, therefore the following capsule making for embodiment 1 carries out toxicity and function test, no longer other formulations is repeated.
Test example 1 toxicology test
The above embodiment of the present invention product promulgates that according to the Ministry of Public Health " health food inspection and assessment technique specification " (version in 2003) related request carries out toxicology test, and concrete test method is shown in above-mentioned specification.
Toxicological experiment proves, the maximum tolerated dose of Kunming mouse acute oral toxicity test is greater than to 20.0g/kg.bw, belongs to nontoxic level; Three genetic toxicity tests (Salmonella reversion test, PCEMNR micronucleus test, mouse sperm deformity test), result is all negative.With the capsule 's content of 1.6g/kg.bw, 2.4g/kg.bw, 3.2g/kg.bw (be equivalent to respectively human body RD 50,75,100 times) to rat oral gavage 30 days, duration of test, each treated animal grows well, and the each dosage of sample is to rat body weight, body weight gain, average food-intake and food utilization do not make significant difference (P>0.05).Each dosage group hematological indices, blood biochemistry index, dirty body ratio and corresponding control group comparison, there was no significant difference (P>0.05), gross anatomy has no the abnormal change relevant with sample with histopathological examination.
Test example 2: function test
Test objective: whether inspection product has the health care that strengthens immunity to animal
The capsule that test material: embodiment 1 makes
Dosage arranges and selects: control group (counting 0.00g/kgbw with primary raw material composition), present composition low dose group (counting 0.15g/kgbw with primary raw material composition), dosage group in the present composition (counting 0.30g/kgbw with primary raw material composition), present composition high dose group (counting 0.60g/kgbw with primary raw material composition), lucidum spore powder group (counting 0.30g/kgbw with primary raw material composition), Astragalus Root P.E group (counting 0.30g/kgbw with primary raw material composition), wherein the present composition is low, in, high dose group is equivalent to respectively 5 of human body RD, 10, 20 times.
Test method: promulgate the method that strengthens immunity function test in " health food inspection and assessment technique specification " (version in 2003) according to the Ministry of Public Health.
Result of the test:
1, body weight
From table 1-5, the each dosage group of the present composition, lucidum spore powder group and Astragalus Root P.E group test initial stage, test mid-term, test Mouse Weight in latter stage and duration of test weight of mice and control group comparison, there are no significant for difference (P>0.05); Dosage group test initial stage in the present composition, test mid-term, test Mouse Weight in latter stage and duration of test weight of mice respectively with lucidum spore powder group and the comparison of Astragalus Root P.E group, there are no significant for difference (P>0.05).
2, internal organs/body weight ratio
From table 6, per os gives the given the test agent 30d of mouse various dose, the each dosage group of the present composition, lucidum spore powder group and Astragalus Root P.E group are to mouse spleen/body weight and thymus gland/body weight ratio and control group comparison, and there are no significant for difference (P>0.05); In the present composition dosage group mouse spleen/body weight and thymus gland/body weight ratio respectively with lucidum spore powder group and the comparison of Astragalus Root P.E group, there are no significant for difference (P>0.05).
The impact of table 6 given the test agent on mouse immune organ/body weight ratio (n=10,
)
Note: with control group comparison, * p<0.05, * * p<0.01; With relatively ， ﹟ P<0.05 ， ﹟ ﹟ P<0.01 of dosage group in the present composition
3, cellular immune function assay result
From table 7, table 8, per os gives the given the test agent 30d of mouse various dose, in the present composition dosage group, present composition high dose group and lucidum spore powder group mouse spleen lymphocyte conversion capability and swelling degree of the paw respectively with control group comparison, difference all has conspicuousness (P<0.05); In the present composition dosage group mice spleen lymphocyte conversion capability respectively with lucidum spore powder group and the comparison of Astragalus Root P.E group, there are no significant for difference (P>0.05); In the present composition dosage group mouse swelling degree of the paw respectively with lucidum spore powder group and the comparison of Astragalus Root P.E group, difference all has conspicuousness (P<0.05).
The impact of table 7 given the test agent on mouse spleen lymphocyte conversion capability experiment (n=10,
)
Note: with control group comparison, * p<0.05, * * p<0.01; With relatively ， ﹟ P<0.05 ， ﹟ ﹟ P<0.01 of dosage group in the present composition
The impact of table 8 given the test agent on mouse delayed allergy (DTH) (n=10,
)
Note: with control group comparison, * p<0.05, * * p<0.01; With relatively ， ﹟ P<0.05 ， ﹟ ﹟ P<0.01 of dosage group in the present composition
4, humoral immune function measurement result
From table 9, table 10, per os gives the given the test agent 30d of mouse various dose, in the present composition dosage group, present composition high dose group, lucidum spore powder group and Astragalus Root P.E group to mouse antibodies cellulation number and HD50 value respectively with control group comparison, difference all has conspicuousness (P<0.05); In the present composition dosage group mouse antibodies cellulation number respectively with lucidum spore powder group and the comparison of Astragalus Root P.E group, difference all has conspicuousness (P<0.01); In the present composition dosage group mouse HD50 value respectively with lucidum spore powder group and the comparison of Astragalus Root P.E group, there are no significant for difference (P>0.05).
The impact of table 9 given the test agent on mouse antibodies cellulation number (n=10,
)
Note: with control group comparison, * p<0.05, * * p<0.01; With relatively ， ﹟ P<0.05 ， ﹟ ﹟ P<0.01 of dosage group in the present composition
The impact of table 10 given the test agent on mouse HD50 value (HC50) (n=10,
)
Note: with control group comparison, * p<0.05, * * p<0.01; With relatively ， ﹟ P<0.05 ， ﹟ ﹟ P<0.01 of dosage group in the present composition
5, monocytes/macrophages functional examination result
From table 11, per os gives the given the test agent 30d of mouse various dose, in the present composition dosage group, present composition high dose group and lucidum spore powder group to mouse monokaryon-macrophage phagocytic index respectively with control group comparison, difference has conspicuousness (P<0.05); In the present composition, dosage group is to mouse monokaryon-macrophage phagocytic index and the comparison of Astragalus Root P.E group, and difference has conspicuousness (P<0.05); In the present composition, dosage group is to mouse monokaryon-macrophage phagocytic index and the comparison of lucidum spore powder group, no significant difference (P>0.05).
From table 12, per os gives the given the test agent 30d of mouse various dose, the each dosage group of the present composition, lucidum spore powder group and Astragalus Root P.E group to mouse macrophage engulf chicken red blood cell ability respectively with control group comparison, there are no significant for difference (P>0.05); In the present composition dosage group to mouse macrophage engulf chicken red blood cell ability respectively with lucidum spore powder group and the comparison of Astragalus Root P.E group, there are no significant for difference (P>0.05).
The impact of table 11 given the test agent on mouse monokaryon-macrophage carbon particle clearance (n=10,
)
Note: with control group comparison, * p<0.05, * * p<0.01; With relatively ， ﹟ P<0.05 ， ﹟ ﹟ P<0.01 of dosage group in the present composition
Table 12 given the test agent on mouse macrophage engulf chicken red blood cell ability and index impact (n=10,
)
Note: with control group comparison, * p<0.05, * * p<0.01; With relatively ， ﹟ P<0.05 ， ﹟ ﹟ P<0.01 of dosage group in the present composition
6, NK cytoactive detection result
From table 13, per os gives the given the test agent of mouse various dose, the NK cells in mice activity of the each dosage group of the present composition, lucidum spore powder group and Astragalus Root P.E group is all significantly higher than control group, and difference all has conspicuousness (P<0.05); In the present composition, dosage group NK cells in mice activity is significantly higher than lucidum spore powder group and Astragalus Root P.E group, and difference all has conspicuousness (P<0.05).
The impact of table 13 given the test agent on NK cells in mice activity (n=10,
)
Note: with control group comparison, * p<0.05, * * p<0.01; With relatively ， ﹟ P<0.05 ， ﹟ ﹟ P<0.01 of dosage group in the present composition
Conclusion: according to above-mentioned result of the test, judge according to the related standards in Ministry of Public Health's promulgation " health food inspection and assessment technique specification " (version in 2003), the present composition, lucidum spore powder and Astragalus Root P.E all have the health care that strengthens immunity of organisms, and in above-mentioned zooperal given the test agent, only have present composition cellular immune function, humoral immune function, monocytes/macrophages function, four result of the tests of NK cytoactive all positive, absolutely prove that the present composition has the effect of comprehensive enhancing immunity of organisms.Above-mentioned animal experiment digital proof simultaneously, the present composition has the effect of more excellent enhancing immunity than single lucidum spore powder preparation under same dose and single Astragalus Root P.E preparation, fully demonstrated effect advantage of composite formula.
The above is only general explanation of the present invention and preferred embodiment; should be understood that; for those skilled in the art; do not departing under the prerequisite of the technology of the present invention principle; can also make some improvements and modifications, these improvements and modifications should be considered as protection scope of the present invention.
Claims (10)
1. for strengthening a composition for immunity of organisms, it is characterized in that, it mainly adopts the raw material of following weight portion to make:
Lucidum spore powder 67-201 part, Astragalus Root P.E 33.5-100.5 part, glossy privet fruit extract 25-75 part, Turmeric P.E 17.5-52.5 part.
2. composition according to claim 1, is characterized in that, it mainly adopts the raw material of following weight portion to make:
134 parts of lucidum spore powders, 67 parts of Astragalus Root P.Es, 50 parts of glossy privet fruit extracts, 35 parts of Turmeric P.Es.
3. composition according to claim 1 and 2, is characterized in that, it also contains one or more auxiliary materials in microcrystalline cellulose, dolomol, dextrin or sucrose, or the conventional pharmaceutical adjunct in other this areas.
4. according to the composition described in claim 1-3 any one, it is characterized in that, described composition is prepared by the following method: get raw material according to above-mentioned weight portion, add appropriate amount of auxiliary materials, all cross after 80 mesh sieves, through batching, mix, make preparation.
5. according to the composition described in claim 1-3 any one, it is characterized in that, described combination dosage form is oral formulations.
6. composition according to claim 5, is characterized in that, described composition oral preparation is that medically acceptable various formulations comprise capsule, tablet, granule or oral liquid, is preferably capsule or tablet.
7. the method for preparing composition described in claim 1-6 any one, is characterized in that, it comprises the steps:
(1) lucidum spore powder, Astragalus Root P.E, glossy privet fruit extract, Turmeric P.E and auxiliary material are crossed respectively to 80 mesh sieves, for subsequent use;
(2) accurately take lucidum spore powder, Astragalus Root P.E, glossy privet fruit extract, Turmeric P.E, put in mixer and mix by formula inventory, add auxiliary material, make preparation.
8. the application of the composition described in claim 1-6 any one in the functional food for the preparation of enhancing immunity of organisms.
9. the composition described in claim 1-6 any one improves the application in the functional food of sub-health state in preparation.
10. contain the functional food of composition described in claim 1-6 any one.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410354033.6A CN104161261A (en) | 2014-07-23 | 2014-07-23 | Composition for strengthening immunity function of organism and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410354033.6A CN104161261A (en) | 2014-07-23 | 2014-07-23 | Composition for strengthening immunity function of organism and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104161261A true CN104161261A (en) | 2014-11-26 |
Family
ID=51905400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410354033.6A Pending CN104161261A (en) | 2014-07-23 | 2014-07-23 | Composition for strengthening immunity function of organism and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104161261A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104623541A (en) * | 2015-01-20 | 2015-05-20 | 北京东方红航天生物技术股份有限公司 | Traditional Chinese medicine conductive to enhancing immunity and preparation method thereof |
| CN105288476A (en) * | 2015-11-13 | 2016-02-03 | 北京元莱健康管理有限公司 | Composition capable of protecting liver and kidney, adjusting immunity and improving constitution, and preparation method thereof |
| CN105999096A (en) * | 2016-07-07 | 2016-10-12 | 天津天狮生物发展有限公司 | Composition for enhancing immunity and application |
| CN109452622A (en) * | 2018-11-15 | 2019-03-12 | 江苏康缘药业股份有限公司 | A kind of compound ganoderma conidia powder and preparation method thereof |
| CN110742270A (en) * | 2019-09-24 | 2020-02-04 | 海南葫芦娃药业集团股份有限公司 | Health food for enhancing immunity and preparation method thereof |
| CN113349364A (en) * | 2021-05-24 | 2021-09-07 | 浙江寿仙谷植物药研究院有限公司 | Application of ganoderma lucidum spore powder in improving learning and memory ability or immunity of children |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1973874A (en) * | 2006-12-07 | 2007-06-06 | 李永胜 | Qizhen capsule and Qizhen oral liquid for strengthening immunity |
| CN103720770A (en) * | 2013-12-20 | 2014-04-16 | 贵州信邦制药股份有限公司 | Glossy privet fruit-astragalus membranaceus effervescent preparation and preparation method thereof |
-
2014
- 2014-07-23 CN CN201410354033.6A patent/CN104161261A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1973874A (en) * | 2006-12-07 | 2007-06-06 | 李永胜 | Qizhen capsule and Qizhen oral liquid for strengthening immunity |
| CN103720770A (en) * | 2013-12-20 | 2014-04-16 | 贵州信邦制药股份有限公司 | Glossy privet fruit-astragalus membranaceus effervescent preparation and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 国食健字G20130747: "中和鸿业牌森源片", 《国家食品药品监督管理总局国产保健食品数据查询》 * |
| 国食健字G20140268: "尚源泰牌凝化胶囊", 《国家食品药品监督管理总局国产保健食品数据查询》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104623541A (en) * | 2015-01-20 | 2015-05-20 | 北京东方红航天生物技术股份有限公司 | Traditional Chinese medicine conductive to enhancing immunity and preparation method thereof |
| CN105288476A (en) * | 2015-11-13 | 2016-02-03 | 北京元莱健康管理有限公司 | Composition capable of protecting liver and kidney, adjusting immunity and improving constitution, and preparation method thereof |
| CN105999096A (en) * | 2016-07-07 | 2016-10-12 | 天津天狮生物发展有限公司 | Composition for enhancing immunity and application |
| CN109452622A (en) * | 2018-11-15 | 2019-03-12 | 江苏康缘药业股份有限公司 | A kind of compound ganoderma conidia powder and preparation method thereof |
| CN110742270A (en) * | 2019-09-24 | 2020-02-04 | 海南葫芦娃药业集团股份有限公司 | Health food for enhancing immunity and preparation method thereof |
| CN113349364A (en) * | 2021-05-24 | 2021-09-07 | 浙江寿仙谷植物药研究院有限公司 | Application of ganoderma lucidum spore powder in improving learning and memory ability or immunity of children |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104161261A (en) | Composition for strengthening immunity function of organism and preparation method thereof | |
| Algethami et al. | Bee pollen: Clinical trials and patent applications | |
| CN116490198A (en) | Aloe-based compositions comprising polysaccharides and polyphenols for modulating immune homeostasis | |
| CN112021555A (en) | Ganoderma lucidum spore powder tablet and preparation method thereof | |
| CN104856968A (en) | Traditional Chinese medicine tablet with effects of removing thrombus and dredging collaterals and preparation method thereof | |
| CN110893197B (en) | Panax notoginseng extract for treating gout and preparation method thereof | |
| CN106361830A (en) | Rhubarb powder and preparation method thereof | |
| CN102805836B (en) | A kind of Chinese medicine composition for the treatment of primary hepatocarcinoma and preparation method thereof | |
| CN1330359C (en) | Chinese medicine preparation for treating AIDS and process thereof | |
| CN1686347A (en) | Ready prepared Chinese medicine for antiaging and remitting body fatigue | |
| CN104082747A (en) | Health food with function of improving body immunity and preparation method of health food | |
| CN111714539B (en) | Liver-protecting composition and preparation method and application thereof | |
| CN103830280A (en) | Preparation method of spirulina extract | |
| CN101904931A (en) | Medicament for treating beriberi and preparation method thereof | |
| CN111214539A (en) | Pig wormwood composite herbaceous plant fermentation traditional Chinese medicine and preparation method thereof | |
| CN101987188B (en) | Biological Chinese patent drug for preventing and treating hyperlipoidemia | |
| CN103919845A (en) | Pharmaceutical composition for improving anoxia endurance and preparation method and application thereof | |
| CN110663948A (en) | Health product with immunity enhancing effect and preparation method thereof | |
| CN104888137A (en) | Medicinal preparation for treatment of polycystic ovarian syndrome | |
| CN103919972B (en) | A kind of pharmaceutical composition of resisting fatigue and its preparation method and application | |
| CN113350469B (en) | Traditional Chinese medicine composition with anti-radiation function, preparation method and application thereof, and product containing traditional Chinese medicine composition | |
| CN104435079A (en) | Traditional Chinese medicinal composition for treating gout | |
| CN103768450B (en) | A kind of Chinese medicine composition and preparation method thereof, preparation and application | |
| CN107136510A (en) | One kind improves immunity health food and preparation method thereof | |
| NL2032218B1 (en) | A Chinese medicinal preparation for preventing and treating duck virus disease, and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141126 |